NASDAQ:PTIE - Pain Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.60 +0.37 (+4.50 %)
(As of 06/25/2018 11:55 AM ET)
Previous Close$8.23
Today's Range$8.35 - $8.6690
52-Week Range$3.10 - $12.80
Volume87,600 shs
Average Volume79,117 shs
Market Capitalization$56.75 million
P/E Ratio-4.73
Dividend YieldN/A
Beta2.69
Pain Therapeutics logoPain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.

Receive PTIE News and Ratings via Email

Sign-up to receive the latest news and ratings for PTIE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PTIE
CUSIP69562K10
Phone512-501-2444

Debt

Debt-to-Equity RatioN/A
Current Ratio14.51
Quick Ratio14.51

Price-To-Earnings

Trailing P/E Ratio-4.73
Forward P/E Ratio-5.21
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.47 per share
Price / Book5.85

Profitability

EPS (Most Recent Fiscal Year)($1.82)
Net Income$-11,910,000.00
Net MarginsN/A
Return on Equity-101.55%
Return on Assets-93.41%

Miscellaneous

Employees9
Outstanding Shares6,900,000

The Truth About Cryptocurrencies

Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions

What is Pain Therapeutics' stock symbol?

Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."

When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?

Pain Therapeutics shares reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.

How were Pain Therapeutics' earnings last quarter?

Pain Therapeutics, Inc. (NASDAQ:PTIE) issued its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.33. View Pain Therapeutics' Earnings History.

When is Pain Therapeutics' next earnings date?

Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Pain Therapeutics.

Who are some of Pain Therapeutics' key competitors?

Who are Pain Therapeutics' key executives?

Pain Therapeutics' management team includes the folowing people:
  • Mr. Remi Barbier, Founder, Chairman, CEO, Pres & Principal Financial Officer (Age 58)
  • Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 75)
  • Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs

Has Pain Therapeutics been receiving favorable news coverage?

News headlines about PTIE stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pain Therapeutics earned a news impact score of 0.16 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.82 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Pain Therapeutics' major shareholders?

Pain Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.55%). View Institutional Ownership Trends for Pain Therapeutics.

Which major investors are buying Pain Therapeutics stock?

PTIE stock was bought by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for Pain Therapeutics.

How do I buy shares of Pain Therapeutics?

Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pain Therapeutics' stock price today?

One share of PTIE stock can currently be purchased for approximately $8.53.

How big of a company is Pain Therapeutics?

Pain Therapeutics has a market capitalization of $56.75 million. The biopharmaceutical company earns $-11,910,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Pain Therapeutics employs 9 workers across the globe.

How can I contact Pain Therapeutics?

Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444.


MarketBeat Community Rating for Pain Therapeutics (PTIE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.